Evidence map›Paper›PMID 25992386›Full record

ArticleEGEMS (Washington, DC)2015

Assessing the potential adoption and usefulness of concurrent, action-oriented, electronic adverse drug event triggers designed for the outpatient setting.

Hillary J Mull, Amy K Rosen, Stephanie L Shimada, Peter E Rivard, Brian Nordberg, Brenna Long, Jennifer M Hoffman, Molly Leecaster, Lucy A Savitz, Christopher W Shanahan and 2 more

Abstract read
In one paragraph

Article in EGEMS (Washington, DC), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Hillary J MullCenter for Healthcare Organization and Implementation Research (CHOIR) ; VA Boston Healthcare System ; Boston University School of Medicine.
Amy K RosenCenter for Healthcare Organization and Implementation Research (CHOIR) ; VA Boston Healthcare System ; Boston University School of Medicine.
Stephanie L ShimadaCenter for Healthcare Organization and Implementation Research (CHOIR) ; Edith Nourse Rogers Memorial Veterans Hospital ; Department of Quantitative Health Sciences, University of Massachusetts Medical School ; Boston University School of Public Health.
Peter E RivardCenter for Healthcare Organization and Implementation Research (CHOIR) ; VA Boston Healthcare System ; Sawyer Business School, Suffolk University.
Brian NordbergHealth Catalyst.
Brenna LongGeriatrics Research Education and Clinical Center, VA Salt Lake City Health Care System ; University of Utah.
Jennifer M HoffmanGeriatrics Research Education and Clinical Center, VA Salt Lake City Health Care System ; University of Utah.
Molly LeecasterGeriatrics Research Education and Clinical Center, VA Salt Lake City Health Care System ; University of Utah.
Lucy A SavitzUniversity of Utah ; Intermountain Healthcare.
Christopher W ShanahanBoston University School of Medicine ; Boston Medical Center.
Amy HelwigOffice of the National Coordinator for Health IT.
Jonathan R NebekerGeriatrics Research Education and Clinical Center, VA Salt Lake City Health Care System ; University of Utah.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAdverse drug event (ADE) detection is an important priority for patient safety research. Trigger tools have been developed to help identify ADEs. In previous work we developed seven concurrent, action-oriented, electronic trigger algorithms designed to prompt clinicians to address ADEs in outpatient care.

objectivesWe assessed the potential adoption and usefulness of the seven triggers by testing the positive predictive validity and obtaining stakeholder input.

methodsWe adapted ADE triggers, "bone marrow toxin-white blood cell count (BMT-WBC)," "bone marrow toxin - platelet (BMT-platelet)," "potassium raisers," "potassium reducers," "creatinine," "warfarin," and "sedative hypnotics," with logic to suppress flagging events with evidence of clinical intervention and applied the triggers to 50,145 patients from three large health care systems. Four pharmacists assessed trigger positive predictive value (PPV) with respect to ADE detection (conservatively excluding ADEs occurring during clinically appropriate care) and clinical usefulness (i.e., whether the trigger alert could change care to prevent harm). We measured agreement between raters using the free kappa and assessed positive PPV for the trigger's detection of harm, clinical usefulness, and both. Stakeholders from the participating health care systems rated the likelihood of trigger adoption and the perceived ease of implementation.

findingsAgreement between pharmacist raters was moderately high for each ADE trigger (kappa free > 0.60). Trigger PPVs for harm ranged from 0 (Creatinine, BMT-WBC) to 17 percent (potassium raisers), while PPV for care change ranged from 0 (WBC) to 60 percent (Creatinine). Fifteen stakeholders rated the triggers. Our assessment identified five of the seven triggers as good candidates for implementation: Creatinine, BMT-Platelet, Potassium Raisers, Potassium Reducers, and Warfarin.

conclusionsAt least five outpatient ADE triggers performed well and merit further evaluation in outpatient clinical care. When used in real time, these triggers may promote care changes to ameliorate patient harm.

Indexed as

adverse drug eventsoutpatient carepatient safetytrigger tools

Identifiers

PMID25992386
PMCPMC4434976

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.